These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 26871295)
21. Variants in microRNA genes in familial papillary thyroid carcinoma. Tomsic J; Fultz R; Liyanarachchi S; Genutis LK; Wang Y; Li W; Volinia S; Jazdzewski K; He H; Wakely PE; Senter L; de la Chapelle A Oncotarget; 2017 Jan; 8(4):6475-6482. PubMed ID: 28031538 [TBL] [Abstract][Full Text] [Related]
22. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. Sun J; Shi R; Zhao S; Li X; Lu S; Bu H; Ma X; Su C J Exp Clin Cancer Res; 2017 Mar; 36(1):40. PubMed ID: 28270228 [TBL] [Abstract][Full Text] [Related]
23. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043 [TBL] [Abstract][Full Text] [Related]
24. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Riquelme I; Tapia O; Leal P; Sandoval A; Varga MG; Letelier P; Buchegger K; Bizama C; Espinoza JA; Peek RM; Araya JC; Roa JC Cell Oncol (Dordr); 2016 Feb; 39(1):23-33. PubMed ID: 26458815 [TBL] [Abstract][Full Text] [Related]
25. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. Qiu Z; Li H; Wang J; Sun C Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684 [TBL] [Abstract][Full Text] [Related]
26. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing. Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845 [TBL] [Abstract][Full Text] [Related]
27. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2. Xue KC; Hu DD; Zhao L; Li N; Shen HY Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989 [TBL] [Abstract][Full Text] [Related]
28. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841 [TBL] [Abstract][Full Text] [Related]
29. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Cahill S; Smyth P; Finn SP; Denning K; Flavin R; O'Regan EM; Li J; Potratz A; Guenther SM; Henfrey R; O'Leary JJ; Sheils O Mol Cancer; 2006 Dec; 5():70. PubMed ID: 17156473 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347 [TBL] [Abstract][Full Text] [Related]
31. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer. Zhao H; Li H Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265 [TBL] [Abstract][Full Text] [Related]
32. LncRNA PFAR facilitates the proliferation and migration of papillary thyroid carcinoma by competitively binding to miR-15a. Fang T; Yu K Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3037-3048. PubMed ID: 37874339 [TBL] [Abstract][Full Text] [Related]
33. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Wang Z; Zhang H; Zhang P; Li J; Shan Z; Teng W Med Oncol; 2013; 30(2):577. PubMed ID: 23609190 [TBL] [Abstract][Full Text] [Related]
34. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study. Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061 [TBL] [Abstract][Full Text] [Related]
35. Identification of key genes and miRNAs markers of papillary thyroid cancer. Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611 [TBL] [Abstract][Full Text] [Related]
36. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway. Wu YC; Li SY; Jia YF Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481 [TBL] [Abstract][Full Text] [Related]
37. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo. Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093 [TBL] [Abstract][Full Text] [Related]
38. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma. Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410 [TBL] [Abstract][Full Text] [Related]
39. Intermediate microRNA expression profile in Graves' disease falls between that of normal thyroid tissue and papillary thyroid carcinoma. Pohl M; Grabellus F; Worm K; Arnold G; Walz M; Schmid KW; Sheu-Grabellus SY J Clin Pathol; 2017 Jan; 70(1):33-39. PubMed ID: 27371612 [TBL] [Abstract][Full Text] [Related]
40. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]